Medicare Part D was implemented 4 years ago. Despite the fact that public-use Part D data were unavailable until late 2008, researchers have used alternate data to examine the effect of Part D on drug use and out-of-pocket costs. In a systematic review of Medline from 2006 to October 2009, the literature about drug use and costs after implementation and during the transition period and coverage gap was summarized. Studies presenting original results regarding drug use and costs after Part D implementation were included. Case reports and series and simulation studies were excluded. Of 552 originally identified articles, 26 met selection criteria: 13 regarding the overall effect of Part D in the year(s) after implementation, seven describing the Part D transition period, and six concerning the coverage gap. Part D implementation was associated with a 6% to 13% increase in drug use and a 13% to 18% decrease in patient costs. The transition period was associated with no significant changes in use or costs for elderly dual-eligible beneficiaries, but effects in other populations were mixed. Entry into the coverage gap was associated with a 9% to 16% decrease in drug use and increases in costs of up to 89%. In summary, studies examining disparate data regarding the implementation of Part D found consistent positive effects on drug use and costs but revealed unfavorable trends in the coverage gap. The effect of the Part D transition period remains unclear. Although public-use data will validate these results, policymakers can use the existing evidence to inform changes and enhancements to Part D immediately. J Am Geriatr Soc 58:1764-1779, 2010. Despite this data limitation, researchers have turned to alternate data sources, including retail pharmacy transaction data and patient self-report surveys, to evaluate the effect of Part D. This systematic review evaluates the peerreviewed literature from 2006 to October 2009 and focuses on studies assessing the effect of Part D on older adults' drug use and out-of-pocket spending for prescription medications. Studies regarding the effect of Part D in the first year(s) of the benefit and in the early months of 2006, known as the transition period, during which many patients with previous drug insurance through Medicaid were automatically transitioned to Part D drug coverage, were examined. Studies that highlighted changes during the coverage gap (doughnut hole) when beneficiaries are responsible for 100% of drug costs were also examined. Taken together, these studies represent the best data available regarding the effect of Part D on Medicare beneficiaries' access to, use of, and spending for prescription drugs. 
T o improve older adults' access to prescription medications, Congress passed the Medicare Prescription Drug Improvement and Modernization Act. 1 The Act established a voluntary prescription drug insurance benefit, known as Medicare Part D (Part D), which began on January 1, 2006. Since the program's inception, policymakers and researchers have been eager to assess the effect of Part D on prescription drug use and beneficiaries' out-of-pocket costs, but the Part D legislation did not allow for use of Medicare prescription drug data for nearly 3 years. To date, 4 years after the inception of Part D, no studies have been published using these data.
Despite this data limitation, researchers have turned to alternate data sources, including retail pharmacy transaction data and patient self-report surveys, to evaluate the effect of Part D. This systematic review evaluates the peerreviewed literature from 2006 to October 2009 and focuses on studies assessing the effect of Part D on older adults' drug use and out-of-pocket spending for prescription medications. Studies regarding the effect of Part D in the first year(s) of the benefit and in the early months of 2006, known as the transition period, during which many patients with previous drug insurance through Medicaid were automatically transitioned to Part D drug coverage, were examined. Studies that highlighted changes during the coverage gap (doughnut hole) when beneficiaries are responsible for 100% of drug costs were also examined. Taken together, these studies represent the best data available regarding the effect of Part D on Medicare beneficiaries' access to, use of, and spending for prescription drugs.
METHODS

Data Sources
A systematic search was performed to identify studies addressing the effect of Medicare Part D implementation on beneficiaries' drug use and out-of-pocket costs. Initial searches were limited to articles published in Medline between January 1, 2006 , and October 31, 2009 . The search focused on any term relating to Medicare Part D (e.g., [Medicare AND drug benefit OR drug plan OR prescription]). Articles containing at least one search term were included in the review. Initial articles were mined for additional reference.
Study Selection
Articles were included if they reported original results, whether drawn from self-report surveys or prescription drug claims. Case reports and series and simulation and modeling studies were excluded. Two reviewers (WS, EK) evaluated the titles and abstracts of search results to identify potentially relevant articles, and two reviewers (JP, EK) assessed complete articles for inclusion.
Data Extraction
Three reviewers (JP, WS, EK) extracted data from selected articles and resolved differences by consensus. Variables assessed included the main research questions, Part D time period assessed, data sources, characteristics of the patient population, study design, results regarding drug use and costs, and patient progression through the four phases of the Part D benefit. Two reviewers [JP, WS] used the Newcastle-Ottawa Scale 2 to assess the quality of each cohort study. Studies were grouped into three main evidence tables: those that focused on the effect of Part D on drug use and costs during the year(s) after implementation (Table 1) , the transition period (Table 2) , and the coverage gap (Table 3) . Data sources for each study are listed in the ''Data Sources and Patient Characteristics'' column of each evidence table.
RESULTS
Of 552 potentially relevant abstracts and titles screened, 42 were evaluated in full, and 26 met all inclusion and exclusion criteria. Thirteen articles described prescription drug use and costs in the year(s) after Part D implementation, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] seven described use and costs during the Part D transition period, [16] [17] [18] [19] [20] [21] [22] and six examined the Part D coverage gap. [23] [24] [25] [26] [27] [28] One study 8 reported data related to the year after implementation and to the coverage gap.
The Overall Effect of Part D in the Year(s) After Implementation
The first study used a random sample of 584,509,537 prescription claims from a large pharmacy chain. 4 Researchers observed a 12.8% absolute increase in days of therapy and an absolute 18.5% decrease in out-of-pocket costs per day of therapy after Part D implementation. A second study using data from the same chain found a 5.9% increase in pill-days and a 13.1% decrease in out-of-pocket expenditures from 2005 to 2006. 5 An assessment using claims from a prescription transaction manager found that patients aged 65 and older filled 8.1% more prescriptions in 2006 than did those aged 58 to 64. Out-of-pocket costs for patients aged 65 and older were 17.2% less than those patients aged 58 to 64 in 2006. 3 In 2006, patients with hyperlipidemia who were newly enrolled in a Medicare Advantage Part D plan filled 44% more monthly prescriptions than in 2005, but newly enrolled Part D patients using oral antidiabetes drugs did not have increases or decreases in use that were measurably different from those of the control group. 10 The out-of- Several studies examined the effect of Part D on specific types of drugs. Using claims from a large pharmacy chain from 2005 to 2006 to examine three psychotropic drug classes, the implementation of Part D was associated with a monthly increase of 1,679 prescriptions for antidepressants and 567 prescriptions for antipsychotics. 6 There were no changes in benzodiazepine use. The proportion of costs paid out of pocket decreased 18% for antidepressants and 21% for antipsychotics but increased 19% for benzodiazepines. A second study in patients who had no drug insurance in 2005 and had the opportunity to enroll in Part D in 2006 examined drug use changes for four drug classes. 8 Defined daily dose increases were observed for statins (22%), clopidogrel (11%), and proton pump inhibitors (PPIs) (37%) during the year after Part D implementation. Warfarin use did not change. Copayments for all drugs except branded omeprazole declined significantly, with monthly copayments per 30 defined daily doses $15 to $80 lower during the stable Part D period than in 2005. In another study using retail pharmacy data, Part D implementation was associated with changes in generic use, which varied according to drug class: increased use of generic angiotensinconverting enzyme inhibitors (10%) and benzodiazepines (19%) but decreases in the use of generic antihyperlipidemics (À 5%), nonsteroidal anti-inflammatories (À 8%), antihistamines (À 25%), and beta-blockers (À 3%). 9 When comparing patients' likelihood to fill a prescription for a generic medication in 2006 with the likelihood in 2005, Part D enrollees were 5% (95% confidence interval (CI) 5 À 6% to À 5%) less likely to fill a prescription for a generic medication in 2006 than in 2005 than were non-enrollees.
Three studies focused on specific populations. Using data from a large long-term care pharmacy provider, one study found little effect of Part D enrollment on long-term nursing home residents. 11 annual decrease in out-of-pocket spending for enrollees.
Changes appeared to be concentrated in those eligible for the low-income subsidy (out-of-pocket 14% of all patients reported that they were required to obtain documentation to continue their prescriptions, a process that for 50% of patients took more than 5 days. 13% reported that they were required to switch a medication, and of those, 60% were required to switch to a generic form.
NA
West et al. 15% of beneficiaries reported decreasing adherence, with 8% reporting they did not refill a prescription (8%)
The most frequently reported cost-coping behavior was switching to a cheaper drug (15%). With regard to financial burden, 5% reported going without another necessity. The Part D Transition Period Most studies of the Part D transition period examined the experiences of patients dually eligible for Medicare and Medicaid. One study spotlighted the experiences of older dually adults using a 5% random sample of pharmacy chain data. The Part D transition appeared to have no effect on medication initiation, continuation, or discontinuation or initiation of a generic drug, with rates of these behaviors comparable in dually eligible elderly patients and in Medicaid patients aged 60 to 63. 16 There were no observed changes in out-of-pocket expenditures. Another study similarly found no drug use differences during the transition period in older dually eligible adults for five drug classes: warfarin, PPIs, statins, clopidogrel, and benzodiazepines. 21 After Part D, elderly dually eligible warfarin users experienced significant decreases in out-of-pocket costs of $0.41 per 30 days' supply, whereas statin, PPI, and clopidogrel payments did not change. Users of benzodiazepines, which were not covered under Part D because of safety concerns, saw copayments increase 91% after the institution of Part D. Drug switching, possibly due to Part D plan coverage, was modest, and no significant differences were seen in 2006 from 2005 in any class studied except PPIs (3.0% switching rate), a class in which all drugs have similar efficacy and safety profiles. One study further explored benzodiazepine use by dually eligible beneficiaries in Florida's Medicaid program, which contracted with an outside pharmacy benefits provider to fill prescriptions not covered by Part D. 18 Seventy percent of all prescriptions filled were for benzodiazepines, suggesting that, because Medicaid programs continued to provide coverage, the goal of Part D of reducing benzodiazepine use was not met. In contrast, another study found Part D transition difficulties in 325 younger dually eligible beneficiaries in Kansas who participated in a telephone survey. 19 During the transition to Part D, 20% reported prescription filling difficulties, and 8% reported discontinuations. Many patients (46%) reported greater out-of-pocket costs under Part D.
In a cross-sectional study of 125 homeless and marginally housed individuals with the human immunodeficiency virus (HIV), 17 of 14 patients who reported HIV treatment interruptions during the first quarter of 2006, 10 (71%) were Part D insured, and nine of these cited plan coverage restrictions as a cause. Of 44 patients who enrolled in Part D, almost 60% reported higher costs for HIV medications, although it is unclear whether all patients were transitioning to Part D, because some had other drug insurance coverage in 2006.
Finally, two studies reported the results of a crosssectional survey of psychiatrists to assess the experiences of dually eligible beneficiaries with mental illness. 20, 22 Psychiatrists Beneficiaries with generic coverage during the gap decreased use by 0.14 prescriptions per month (decrease of 0.5 brand name and increase of 0.36 generic drugs).
Those with generic coverage during the gap filled an average of 16 monthly generic prescriptions; those without generic coverage filled 8.
9
CI 5 confidence interval; DDD 5 defined daily dose.
surveyed reported that 44% of their 1,816 dually eligible patients experienced a psychiatric medication access problem during the transition period. Of these, 35% were unable to access refills or new prescriptions, 19% were switched to a different drug because of coverage limitations, and 22% had access difficulties because of cost.
20
The Effect of Part D in the Coverage Gap One study focused on Part D enrollees who reached the coverage gap by June but did not reach the catastrophic coverage period in 2006. 27 Enrollees had an average of 16% fewer prescription days purchased in the coverage gap than nonenrollees who reached the coverage gap spending threshold but did not experience a gap. After reaching the coverage gap spending threshold, generic drug use increased 25% in the Part D group but only 5% in the non-enrollee group. Average total costs in the Part D group decreased 28% in the coverage gap, but out-of-pocket costs increased 89%, whereas total costs in the non-enrollee group increased 2%, and out-of-pocket costs decreased 6%. Similar drug use decreases of 14% were found in the coverage gap for Medicare Advantage Part D plan enrollees. 28 It was observed that patients who reached the coverage gap filled an average of 4.86 prescriptions per 30 days in the initial coverage period and 4.40 prescriptions per 30 days in the coverage gapF9.5% fewer. 25 In another study, prescription use during the coverage gap also showed per-month declines: clopidogrel À 5%, warfarin À 4.8%, and statins À 6.3%. 8 Out-of-pocket expenditures during the coverage gap increased between $12 (warfarin) and $65 (clopidogrel) per 30 defined daily doses from pre-coverage gap costs.
In examining adherence, one study noted that declines in medication adherence were similar for Part D enrollees who experienced a gap in coverage and non-enrollees who reached the coverage gap spending threshold (but whose coverage was uninterrupted) with the exception of two drug classesFantihypertensive and antidiabetic agentsFfor which discontinuation rates were higher for Part D enrollees in the coverage gap. 26 Another study found that, in the coverage gap, 20% of Part D enrollees discontinued a medication because of cost, compared with only 5% of nonenrollees who reached the coverage gap spending threshold. 23 Part D enrollees were 5 times (95% CI 5 2-13%) as likely to use medication costlowering strategies in the gap as were non-enrollees. Among Part D enrollees who did and did not reach the coverage gap in 2006, a survey which asked about their drug cost-coping behaviors found that the 36% of beneficiaries who knew about the gap were 11% (95% CI 5 0.8-21.9%) more likely to report a behavior to reduce drug costs than beneficiaries who were not aware of the coverage gap. 24 
DISCUSSION
This review identified 26 studies evaluating the effect of Medicare Part D implementation on drug use and out-ofpocket costs. As expected, the inception of Part D was associated with a consistent overall increase in drug use and a decrease in out-of-pocket costs for enrollees. The transition to Part D went smoothly for many older dually eligible patients, but other vulnerable populations appear to have experienced difficulties. Finally, the Part D coverage gap was associated with less drug use and higher out-of-pocket costs.
There was little variation in effect estimates between studies evaluating the effect of Part D implementation: a 6% to 13% increase in drug use and a 13% to 18% decrease in out-of-pocket drug costs. Changes in use and costs varied according to drug, disease, and population studied, underscoring the need to consider such factors when assessing the effect of Part D, although there was little indication that Part D selectively led to greater use of essential, underused drugs than of overused medications. 13 In studies of the Part D transition period, elderly dually eligible beneficiaries generally fared well, whereas other populations seemed to experience problems. Two hypotheses may explain these disparate experiences. Because of concerns about the Part D transition for dually eligible beneficiaries, many of whom are elderly, the Centers for Medicare and Medicaid Services and the states instituted a variety of mechanisms to ease the change, including autoenrollment and temporary continuation of Medicaid drug coverage during early 2006. 29 In contrast, vulnerable populations, such as those with HIV or mental illness, may have had difficulties with the transition because of factors associated with their illnesses.
A second hypothesis is that studies using claims data were unable to identify medication access problems because claims reflected only successfully filled prescriptions, not attempted fills, whereas the survey-based studies were able to uncover these problems. Using claims data, no changes were seen in medication continuity for benzodiazepines. 26 Similar methodology might be used to examine continuity of other medications during the transition period, shedding light on the ability of drug claims versus survey-based data to expose medication access problems.
Finally, across all studies, entry of Part D beneficiaries into the coverage gap was associated with 9% to 16% less drug use (of an amount similar in magnitude to the increases seen after Part D implementation) and higher out-of-pocket costs, with changes as high as 89%. Patients who entered the coverage gap were 5% to 11% more likely to report discontinuing, switching, or failing to initiate a medication than were patients who did not enter the coverage gap. Use of generic drugs increased 20% during the coverage gap. These studies suggest that, when patients enter the coverage gap, the cost burden dramatically and immediately affects drug use and moves patients towards more-affordable generic drugs.
The consistency of these findings has important implications. Similarly structured benefit gaps (e.g., drug caps) have been associated with adverse outcomes such as death and greater nonelective healthcare use. 30 As Part D reforms are implemented, policymakers and researchers must evaluate whether drug cost savings during the gap offset the benefits of drug coverage, with the gap potentially leading to adverse health outcomes and even greater spending on healthcare services.
The conclusions drawn from studies in this systematic review must be interpreted with caution. Even though research has found that elderly patients fill 97% of prescriptions within a single pharmacy chain, 31 studies that rely on retail prescription claims may miss prescriptions for patients who use more than one pharmacy chain. Studies evaluating patients without prior drug insurance did not have Part D enrollment files for patients but rather estimated Part D coverage using cost algorithms, so there is probably some misclassification. Finally, these studies offer little or no evidence regarding the effect of Part D on health outcomes. Because the primary goal of Part D was to improve the health of Medicare beneficiaries, such studies are desperately needed.
Using different data sources, designs, and analytical approaches, the studies included in this systematic review showed consistent estimates of the effect of Part D in the initial year(s) of the benefit, as well as during the coverage gap period. Conflicting results regarding the Part D transition period can be further examined using existing data and methodologies applied to specific drug classes and populations. Although studies that employ public-use Part D claims are eagerly awaited, the currently available evidence documents the role of Part D in improving medication access for Medicare beneficiaries and highlights Part D benefit features such as the coverage gap that merit reconsideration and potential improvement. As the fate of the Part D benefit and the coverage gap are pondered, data about effects on health outcomes are urgently needed. Author Contributions: Dr. Polinski, Dr. Shrank, and Dr. Schneeweiss participated in the conception and design, acquisition of data, writing and critical review of the manuscript, data analysis, and obtaining funding. Dr. Polinski had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Ms. Kilabuk participated in the conception and design, acquisition of data, writing and critical review of the manuscript, and data analysis. Dr. Brennan participated in the conception and design, critical review of the manuscript, and data analysis.
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